相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials
W. Rungapiromnan et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C. M. van de Kerkhof et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
Alexis Ogdie et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the USA: 2005-09
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Michelle A. Lowes et al.
TRENDS IN IMMUNOLOGY (2013)
Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies
Ehrin J. Armstrong et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events
Nehal N. Mehta et al.
AMERICAN JOURNAL OF MEDICINE (2011)
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis
Eiko Toichi et al.
JOURNAL OF IMMUNOLOGY (2006)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques
AB Gottlieb et al.
JOURNAL OF IMMUNOLOGY (2005)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris
E Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)